Abstract
Objective: To analyze the benefits of treatment with Recombinant Human Leptin in areas presenting Lipodystrophy and its impacts on serum levels of Glycemia and Glycated Hemoglobin. Methods: This is an integrative review, in which data collection was conducted in the PubMed database. Twelve articles were selected from the period 2002 to 2020. Results: Treatment of Lipodystrophy through Recombinant Human Leptin has been studied over the years to prevent and delay the onset of this alteration. Leptin replacement is performed in individuals with Lipodystrophy. Administration of this hormone attenuated hypoleptinemia, and consequently moderated adipose tissue degradation and glycemic control, resulting in improved insulin resistance. Conclusion: It is concluded that treatment with leptin directly influences the improvement of clinical and laboratory signs of Lipodystrophy, preventing rapid progression of adipose tissue degradation and glycemic imbalance, as well as reducing levels of Glycated Hemoglobin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
